Prioritizing Equity in Antimicrobial Stewardship Efforts (EASE): A Framework for Infectious Diseases Clinicians (CE Session)
Includes a Live Web Event on 04/30/2025 at 10:25 AM (PDT)
Description:
This session is part of the Sepsis Alliance AMR Conference 2025.
This presentation discusses the impact of systems of oppression and inequities in social determinants of health on Antimicrobial Stewardship. It also provides a framework for clinicians to consider when identifying and mitigating disparities at their institutions.
Learning Objectives:
At the end of the session, the learner should be able to:
- Describe the relationship between systemic racism, social determinants of health, and the treatment of patients with infections;
- Identify factors in antimicrobial stewardship processes and policies that could result in disparities in care;
- Utilize the Prioritizing Equity in Antimicrobial Stewardship Efforts (EASE). Framework to evaluate and reduce health disparities in antimicrobial use in individual practice settings.
Target Audience:
Nurses, advanced practice providers, physicians, emergency responders, pharmacists, medical technologists, respiratory therapists, physical/occupational therapists, infection prevention specialists, data/quality specialists, and more.
Jacinda (JAM). Abdul-Mutakabbir, PharmD, MPH, AAHIVP
Assistant Professor of Clinical Pharmacy
University of California San Diego
Jacinda Abdul-Mutakabbir (JAM), PharmD, MPH, AAHIVP, is an Assistant Professor of Clinical Pharmacy at the University of California San Diego in the Skaggs School of Pharmacy and Pharmaceutical Sciences and the Division of the Black Diaspora and African American Studies. Her research is based on antimicrobial resistance and stewardship, where she identifies health disparities in various infectious diseases to inform tailored interventions for vulnerable communities. She has published over 60 articles, including several focused on identifying racial and social vulnerability differences in various infectious disease states, including Clostridium difficile infection, candidemia, and others. She was recognized as a top scientist under 30 for her early contributions to antimicrobial resistance research by the European Society of Clinical Microbiology and Infectious Diseases in 2020. Additionally, the United States Public Health Services has recognized her dedication to improving public health, as she was the 2017 recipient of the USPHS Outstanding Service Award, and she currently serves as an appointed member of the CVSH Health Equity National Advisory Board. In 2021, she received the Society of Infectious Disease Pharmacists (SIDP) Gita Patel Best Practice Award and the Wayne State University Warrior of Distinction of Alumni Award. In 2023, Dr. Abdul-Mutakabbir was named the recipient of the Infectious Diseases Society of America (IDSA) Clinical Practice Innovation Award, and in 2024, she received the American College of Clinical Pharmacy (ACCP) New Clinical Practitioner Award. Most recently, she was an appointed editor for Clinical Microbiology Reviews, an American Society of Microbiology (ASM) Journal. Dr. Abdul-Mutakabbir continues to be an active member of several professional organizations, including the American College of Clinical Pharmacy (ACCP), the American Society of Microbiology (ASM), the Infectious Diseases Society of America (IDSA), and the Society for Healthcare Epidemiology of America (SHEA).